VEGFR-1, Bcl-2, and HO-1 Ratios in Pregnant Women With Hypertension

Basit Öğe Kaydı
dc.authorwosidSAYIN, N. CENK/A-5801-2018
dc.contributor.authorVarol, Fusun
dc.contributor.authorUzunoglu, Renginar
dc.contributor.authorErbas, Hakan
dc.contributor.authorSut, Necdet
dc.contributor.authorSayin, Cenk
dc.date.accessioned2024-06-12T11:12:48Z
dc.date.available2024-06-12T11:12:48Z
dc.date.issued2015
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackgound/Aim: Preeclampsia (PE) is a multisystem disease resulting in high maternal-fetal morbidity and mortality. The aim of the study was to investigate antiangiogenesis-associated alterations in antiapoptotic and antioxidative proteins in PE. Method: Of the 46 patients with PE, 25 (54.3%) were with gestational hypertension (GH), 12 (26%) were with mild, and 9 (19.5%) were with severe PE. The serum levels of vascular endothelial growth factor receptor 1 (VEGFR-1), heme oxygenase 1 (HO-1), and B-cell lymphoma/leukemia (Bcl-2) levels were measured by enzyme-linked immunosorbent assay. Results: In the severe PE group, the VEGFR-1 serum levels (27.3 16.8 vs 13.3 +/- 10.7 ng/mL, P = .023) were higher, but the Bcl-2 levels (1.5 +/- 0.2 vs 2.1 +/- 1.7 ng/mL, P = .047) were lower than the levels in the GH-mild PE group (P = .047). Also, VEGFR-1/Bcl-2 ratio in the severe PE group was significantly higher (P = .003) than the ratio in the GH-mild PE group. Conclusion: The Bcl-2 and HO-1 proteins seem to have important roles in the antiangiogenic environment of preeclampsia.en_US
dc.description.sponsorshipTrakya University, TUBAP [2010-53]en_US
dc.description.sponsorshipThe author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Supported by a grant at Trakya University, TUBAP, no. 2010-53.en_US
dc.identifier.doi10.1177/1076029613498816
dc.identifier.endpage288en_US
dc.identifier.issn1076-0296
dc.identifier.issn1938-2723
dc.identifier.issue3en_US
dc.identifier.pmid23925400en_US
dc.identifier.scopus2-s2.0-84924908480en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage285en_US
dc.identifier.urihttps://doi.org/10.1177/1076029613498816
dc.identifier.urihttps://hdl.handle.net/20.500.14551/23294
dc.identifier.volume21en_US
dc.identifier.wosWOS:000350492800014en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSage Publications Incen_US
dc.relation.ispartofClinical And Applied Thrombosis-Hemostasisen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPreeclampsiaen_US
dc.subjectVEGFR-1en_US
dc.subjectBcl-2en_US
dc.subjectHO-1en_US
dc.subjectEndothelial Growth-Factoren_US
dc.subjectHeme Oxygenase-1en_US
dc.subjectInductionen_US
dc.subjectExpressionen_US
dc.subjectReceptoren_US
dc.titleVEGFR-1, Bcl-2, and HO-1 Ratios in Pregnant Women With Hypertensionen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu